Meridian Wealth Management LLC Sells 97 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Meridian Wealth Management LLC trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 922 shares of the biopharmaceutical company’s stock after selling 97 shares during the period. Meridian Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $657,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Rakuten Securities Inc. grew its holdings in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $26,000. Private Wealth Management Group LLC grew its holdings in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 39 shares during the last quarter. Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $49,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $675.49 on Wednesday. The company’s 50-day moving average price is $697.13 and its 200-day moving average price is $859.13. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market cap of $73.85 billion, a P/E ratio of 17.65, a P/E/G ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm earned $11.86 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analyst Ratings Changes

Several brokerages recently commented on REGN. Bernstein Bank dropped their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Oppenheimer dropped their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Finally, Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.